Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

Running, not enrolling · Not applicable

Conditions studied: Kidney Cancer

In brief

The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.

Key facts

Study ID: NCT04922307
Run by: Vanderbilt University Medical Center
People needed: 240
Starts: 2021-07-23
Expected to finish: 2027-06-15
Last updated by the study team: 2025-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Renal masses ≥ cT2 (by any conventional imaging).
N1 or M1 disease is allowed if they are deemed surgical candidates (including cytoreductive nephrectomy).
Male and female patients.
18 and older.
Ejection fraction (EF) ≥ 45% by echocardiogram (ECHO).
Adequate organ function as defined by:
Hemoglobin ≥ 9 g/dL. Pre-operative allogenic blood transfusion is allowed.
Platelets ≥ 100.000/μl.
Albumin ≥ 2.5 g/dL.
Aspartate Aminotransferase (AST) and alanine transaminase (ALT) ≤ 75U/L or total bilirubin ≤ 2.0 mg/dL.
WBC within institutional normal limits.
PT within institutional normal limits.
INR < 1.5 and PTT normal.
Consent and compliance with all aspects of the study protocol.

You may not qualify if…

Male and female younger than 18 years old.
Non-surgical candidate
Unstable angina.

Where it is running

H. Lee Moffitt Cancer Center — Tampa, Florida, United States
Winship Cancer Institute at Emory University — Atlanta, Georgia, United States
Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.